Market Closed -
Hong Kong S.E.
04:08:22 2024-05-10 am EDT
|
5-day change
|
1st Jan Change
|
5.89
HKD
|
+5.56%
|
|
+16.17%
|
+14.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
45,437
|
25,004
|
22,303
|
39,705
|
32,229
|
37,004
|
-
|
-
|
Enterprise Value (EV)
1 |
74,178
|
57,928
|
61,337
|
73,426
|
68,431
|
70,072
|
68,598
|
63,565
|
P/E ratio
|
13.9
x
|
7.65
x
|
5.92
x
|
9.58
x
|
8.41
x
|
8.26
x
|
7.31
x
|
6.86
x
|
Yield
|
1.52%
|
3.02%
|
4.23%
|
2.53%
|
3%
|
2.8%
|
3.13%
|
3.3%
|
Capitalization / Revenue
|
0.22
x
|
0.12
x
|
0.09
x
|
0.16
x
|
0.13
x
|
0.13
x
|
0.12
x
|
0.11
x
|
EV / Revenue
|
0.36
x
|
0.29
x
|
0.26
x
|
0.29
x
|
0.28
x
|
0.25
x
|
0.22
x
|
0.19
x
|
EV / EBITDA
|
5.9
x
|
4.91
x
|
4.83
x
|
4.38
x
|
4.82
x
|
4.28
x
|
3.77
x
|
3.34
x
|
EV / FCF
|
11.3
x
|
8.86
x
|
5.88
x
|
7.47
x
|
-
|
13.5
x
|
10.1
x
|
7.04
x
|
FCF Yield
|
8.82%
|
11.3%
|
17%
|
13.4%
|
-
|
7.41%
|
9.94%
|
14.2%
|
Price to Book
|
1.12
x
|
0.54
x
|
0.44
x
|
0.8
x
|
0.35
x
|
0.72
x
|
0.63
x
|
0.57
x
|
Nbr of stocks (in thousands)
|
6,284,506
|
6,282,510
|
6,282,510
|
6,282,510
|
6,282,510
|
6,282,510
|
-
|
-
|
Reference price
2 |
7.230
|
3.980
|
3.550
|
6.320
|
5.130
|
5.890
|
5.890
|
5.890
|
Announcement Date
|
3/30/20
|
3/26/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
204,454
|
200,423
|
236,806
|
254,106
|
244,704
|
280,273
|
311,708
|
340,564
|
EBITDA
1 |
12,576
|
11,790
|
12,690
|
16,775
|
14,191
|
16,364
|
18,182
|
19,035
|
EBIT
1 |
10,212
|
9,346
|
9,868
|
13,623
|
11,027
|
13,524
|
14,814
|
15,886
|
Operating Margin
|
4.99%
|
4.66%
|
4.17%
|
5.36%
|
4.51%
|
4.83%
|
4.75%
|
4.66%
|
Earnings before Tax (EBT)
1 |
6,640
|
7,076
|
8,408
|
9,856
|
9,880
|
11,585
|
12,932
|
14,152
|
Net income
1 |
3,286
|
3,297
|
3,769
|
4,147
|
3,854
|
4,575
|
5,118
|
5,442
|
Net margin
|
1.61%
|
1.65%
|
1.59%
|
1.63%
|
1.58%
|
1.63%
|
1.64%
|
1.6%
|
EPS
2 |
0.5200
|
0.5200
|
0.6000
|
0.6600
|
0.6100
|
0.7129
|
0.8057
|
0.8590
|
Free Cash Flow
1 |
6,544
|
6,537
|
10,428
|
9,833
|
-
|
5,191
|
6,817
|
9,035
|
FCF margin
|
3.2%
|
3.26%
|
4.4%
|
3.87%
|
-
|
1.85%
|
2.19%
|
2.65%
|
FCF Conversion (EBITDA)
|
52.04%
|
55.45%
|
82.17%
|
58.62%
|
-
|
31.72%
|
37.49%
|
47.47%
|
FCF Conversion (Net income)
|
199.13%
|
198.27%
|
276.68%
|
237.09%
|
-
|
113.47%
|
133.2%
|
166.02%
|
Dividend per Share
2 |
0.1100
|
0.1200
|
0.1500
|
0.1600
|
0.1540
|
0.1648
|
0.1845
|
0.1945
|
Announcement Date
|
3/30/20
|
3/26/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
102,531
|
89,387
|
111,036
|
114,488
|
122,319
|
125,716
|
128,390
|
138,940
|
105,764
|
143,963
|
128,572
|
160,464
|
143,838
|
EBITDA
|
-
|
-
|
4,573
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
3,711
|
6,481
|
4,058
|
7,822
|
5,801
|
7,745
|
3,282
|
8,513
|
5,269
|
9,761
|
5,277
|
Operating Margin
|
-
|
-
|
3.34%
|
5.66%
|
3.32%
|
6.22%
|
4.52%
|
5.57%
|
3.1%
|
5.91%
|
4.1%
|
6.08%
|
3.67%
|
Earnings before Tax (EBT)
|
-
|
-
|
2,586
|
-
|
-
|
-
|
-
|
7,117
|
2,763
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
719.9
|
-
|
-
|
-
|
-
|
3,038
|
816.2
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
0.65%
|
-
|
-
|
-
|
-
|
2.19%
|
0.77%
|
-
|
-
|
-
|
-
|
EPS
2 |
0.0400
|
0.4100
|
0.1100
|
0.3900
|
0.2100
|
0.4800
|
0.1800
|
-
|
0.1300
|
0.4900
|
0.2100
|
0.5600
|
0.1900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
8/27/20
|
3/26/21
|
8/25/21
|
3/29/22
|
8/25/22
|
3/30/23
|
8/31/23
|
3/26/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
28,741
|
32,924
|
39,035
|
33,720
|
36,202
|
33,068
|
31,594
|
26,561
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.285
x
|
2.792
x
|
3.076
x
|
2.01
x
|
2.551
x
|
2.021
x
|
1.738
x
|
1.395
x
|
Free Cash Flow
1 |
6,544
|
6,537
|
10,428
|
9,833
|
-
|
5,191
|
6,817
|
9,035
|
ROE (net income / shareholders' equity)
|
8.21%
|
7.56%
|
7.73%
|
8.25%
|
8.61%
|
8.47%
|
8.75%
|
8.23%
|
ROA (Net income/ Total Assets)
|
1.8%
|
1.65%
|
1.65%
|
1.69%
|
1.67%
|
2.3%
|
2.4%
|
2.3%
|
Assets
1 |
183,087
|
199,693
|
228,973
|
244,931
|
231,152
|
199,308
|
213,439
|
236,776
|
Book Value Per Share
2 |
6.480
|
7.400
|
8.110
|
7.890
|
14.80
|
8.220
|
9.300
|
10.30
|
Cash Flow per Share
2 |
1.910
|
2.140
|
2.040
|
5.140
|
-
|
2.000
|
1.280
|
1.340
|
Capex
1 |
1,597
|
1,669
|
2,415
|
2,798
|
-
|
3,446
|
3,946
|
4,057
|
Capex / Sales
|
0.78%
|
0.83%
|
1.02%
|
1.1%
|
-
|
1.23%
|
1.27%
|
1.19%
|
Announcement Date
|
3/30/20
|
3/26/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
-
|
Last Close Price
5.89
HKD Average target price
7.424
HKD Spread / Average Target +26.05% Consensus |
1st Jan change
|
Capi.
|
---|
| +14.81% | 4.74B | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|